Free Trial
→ Think NVDA’s run was epic? You ain’t seen nothin’ yet (From Timothy Sykes) (Ad) Buy RDHL Stock  Free RDHL Stock Alerts

Redhill Biopharma (RDHL) SEC Filings & 10K Form

Redhill Biopharma logo
$1.84 +0.07 (+4.15%)
Closing price 06/18/2025 03:59 PM Eastern
Extended Trading
$1.80 -0.04 (-2.17%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Recent Redhill Biopharma SEC Filings

Export to Excel
DateFilerForm TypeView
05/27/2025
6:00 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/13/2025
6:04 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/05/2025
7:04 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/02/2025
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2025
6:05 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/17/2025
3:06 PM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2025
6:02 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/10/2025
6:51 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/10/2025
6:36 AM		Redhill Biopharma (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
04/08/2025
6:00 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/26/2025
6:00 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/18/2025
6:02 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/12/2025
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/27/2025
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/25/2025
6:04 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/04/2025
6:04 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/03/2025
3:28 PM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/03/2025
3:05 PM		Redhill Biopharma (Filer)
Form 424B5
01/21/2025
6:05 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/10/2024
6:03 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/02/2024
6:03 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/14/2024
11:22 AM		CVI Investments, Inc. (Filed by)
Redhill Biopharma (Subject)
Form SC 13G/A
10/28/2024
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/22/2024
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/15/2024
5:02 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/01/2024
6:02 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/30/2024
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/18/2024
8:00 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/17/2024
8:13 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/09/2024
6:04 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/05/2024
7:30 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/05/2024
6:05 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/03/2024
6:03 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/29/2024
6:07 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/26/2024
6:02 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/21/2024
6:04 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/19/2024
11:15 PM		Redhill Biopharma (Filer)
Form EFFECT
08/19/2024
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/16/2024
6:13 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/13/2024
12:37 PM		Redhill Biopharma (Filer)
Form 424B3
08/13/2024
7:35 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Why Is President Trump Fast-Tracking These Companies? (Ad)

Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administration has begun to fast-track the operations of a handful of companies… Accelerating their potential profits. That's why legendary investor Louis Navellier is now recommending these three stocks that are being fast-tracked.

Click here to see the details on what the Financial Times called...
08/09/2024
6:01 AM		Redhill Biopharma (Filer)
Form F-3
Registration statement for securities of certain foreign private issuers  
08/07/2024
3:43 PM		Quintairos, Prieto, Wood & Boyer P.A. (Filed by)
Redhill Biopharma (Subject)
Form SCHEDULE 13D
08/07/2024
8:51 AM		Redhill Biopharma (Filer)
Form 424B3
08/06/2024
6:00 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/01/2024
6:05 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/22/2024
6:04 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/09/2024
7:03 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/20/2024
6:23 AM		Redhill Biopharma (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
(Data available from 1/1/2016 forward)


Related Companies and Tools

Related Companies
SEC Filings Tools

This page (NASDAQ:RDHL) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners
379 passengers walked away from this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
The IRS Loophole That Lets You Own Gold Tax-Free
What if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...
Advantage Gold | Sponsored
Why Is President Trump Fast-Tracking These Companies?
Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...
InvestorPlace | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump c...
Weiss Ratings | Sponsored
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...
American Alternative | Sponsored
An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Trump Makes Major Crypto Announcement
Trump's crypto revolution is now fully underway and now, we believe he’s about to deliver on his biggest promi...
Crypto 101 Media | Sponsored
Most Bitcoin holders have no idea this exists
Here’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...
Brownstone Research | Sponsored